What question did this study set out to answer?

To evaluate the tumor targeting, pharmacokinetics, and thermoablative therapeutic efficacy of 111In-ChL6 monoclonal antibody-conjugated iron oxide nanoparticles activated by an alternating magnetic field in breast cancer xenografts.

October 1, 2005Clinical Cancer Research

Development of Tumor Targeting Bioprobes (111In-Chimeric L6 Monoclonal Antibody Nanoparticles) for Alternating Magnetic Field Cancer Therapy

View Full Paper

Ask AI

Bookmark

Authors

SDSally J. DeNardoLawrence Livermore National Laboratory GDGerald L. DeNardoKanazawa University LMLaird MiersShriners Hospitals for Children - Erie

Discussion

Member takes

Implication

Animal study demonstrates that antibody-guided iron oxide nanoparticles combined with alternating magnetic fields induce tumor necrosis in breast cancer xenografts, suggesting thermoablative utility.

Key Points

To evaluate the tumor targeting, pharmacokinetics, and thermoablative therapeutic efficacy of 111In-ChL6 monoclonal antibody-conjugated iron oxide nanoparticles activated by an alternating magnetic field in breast cancer xenografts.
Conjugated 111In-ChL6 monoclonal antibodies to 20-nm dextran-coated iron oxide nanoparticles and administered them intravenously into athymic mice bearing human breast cancer HBT 3477 xenografts.
Applied a 153 kHz alternating magnetic field (AMF) at amplitudes of 700, 1,000, or 1,300 Oe at 72 hours post-injection, comparing outcomes against untreated, AMF-only, and nanoparticle-only control groups.
Combined AMF and bioprobe therapy resulted in up to an eightfold longer mean time to quintuple tumor volume compared with untreated controls (P = 0.0013).
Toxicity was confined to the 1,300 Oe AMF cohort (4 of 12 immediate deaths and skin erythema), while electron microscopy confirmed bioprobe localization on tumor cell surfaces and necrosis within 24 hours of therapy.

Cite This Study

DeNardo et al. (2005) studied this question.

synapsesocial.com/papers/6a71dada5d37378ac1deddff https://doi.org/10.1158/1078-0432.ccr-1004-0022

View Full Paper

Ask AI

Bookmark

Implication

Animal study demonstrates that antibody-guided iron oxide nanoparticles combined with alternating magnetic fields induce tumor necrosis in breast cancer xenografts, suggesting thermoablative utility.

Development of Tumor Targeting Bioprobes (111In-Chimeric L6 Monoclonal Antibody Nanoparticles) for Alternating Magnetic Field Cancer Therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Development of Tumor Targeting Bioprobes (111In-Chimeric L6 Monoclonal Antibody Nanoparticles) for Alternating Magnetic Field Cancer Therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider